---
figid: PMC9650829__40164_2022_352_Fig2_HTML
figtitle: 'Understanding the versatile roles and applications of EpCAM in cancers:
  from bench to bedside'
organisms:
- Mus musculus
- Hepatitis B virus
- Bougainvillea spectabilis
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC9650829
filename: 40164_2022_352_Fig2_HTML.jpg
figlink: /pmc/articles/PMC9650829/figure/Fig2/
number: F2
caption: Roles of EpCAM in cancer development and progression. a EpCAM on CSCs membrane
  surface was cleaved by ADAM17 and γ-secretase, generating EpICD. Most of the EpICD
  is degraded by proteasome, while the remaining EpICD can bind with FHL2, β-catenin
  and Lef-1, forming the trans-nuclear complex to activate proliferation and pluripotency
  related genes. b EpEX/EGFR pathway and EpICD trans-nuclear complex can promote cell
  proliferation. EGF and TGF-β pathway can regulate EMT markers and EpCAM expression.
  c In hypoxic condition, EpCAM is upregulated in ATP-high state, whereas in ATP-low
  situation, HIF-1α is upregulated. CAIX is overexpressed mediated by HIF-1α. CAIX+,
  together with higher EpCAM and K19 expression HCC subgroup exhibited with high resistance
  to chemoembolization. Additionally, N-glycosylated EpCAM can regulate HIF-1α and
  promote EMT and stemness related properties. d MHC-I/TCR interaction serves as T
  cell activation signals. While activated EpEX/EGFR/ERK pathway results in reduction
  of PD-L1 ubiquitination degradation. PD-L1 on tumor surface hampers activation of
  CD8+ T cells and leading to immune escape. CAIX carbonic anhydrase-IX, ECM extracellular
  matrix, FHL2 four and a half LIM domain protein 2, HIF-1α hypoxia inducible factor
  1α, K19 keratin 19, Lef-1 lymphoid enhancer factor 1
papertitle: 'Understanding the versatile roles and applications of EpCAM in cancers:
  from bench to bedside.'
reftext: Yiyang Liu, et al. Exp Hematol Oncol. 2022;11:97.
year: '2022'
doi: 10.1186/s40164-022-00352-4
journal_title: Experimental Hematology & Oncology
journal_nlm_ta: Exp Hematol Oncol
publisher_name: BioMed Central
keywords: EpCAM | Cancer | Cell signaling | Extracellular vesicles | Immune | Therapy
automl_pathway: 0.9542627
figid_alias: PMC9650829__F2
figtype: Figure
redirect_from: /figures/PMC9650829__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9650829__40164_2022_352_Fig2_HTML.html
  '@type': Dataset
  description: Roles of EpCAM in cancer development and progression. a EpCAM on CSCs
    membrane surface was cleaved by ADAM17 and γ-secretase, generating EpICD. Most
    of the EpICD is degraded by proteasome, while the remaining EpICD can bind with
    FHL2, β-catenin and Lef-1, forming the trans-nuclear complex to activate proliferation
    and pluripotency related genes. b EpEX/EGFR pathway and EpICD trans-nuclear complex
    can promote cell proliferation. EGF and TGF-β pathway can regulate EMT markers
    and EpCAM expression. c In hypoxic condition, EpCAM is upregulated in ATP-high
    state, whereas in ATP-low situation, HIF-1α is upregulated. CAIX is overexpressed
    mediated by HIF-1α. CAIX+, together with higher EpCAM and K19 expression HCC subgroup
    exhibited with high resistance to chemoembolization. Additionally, N-glycosylated
    EpCAM can regulate HIF-1α and promote EMT and stemness related properties. d MHC-I/TCR
    interaction serves as T cell activation signals. While activated EpEX/EGFR/ERK
    pathway results in reduction of PD-L1 ubiquitination degradation. PD-L1 on tumor
    surface hampers activation of CD8+ T cells and leading to immune escape. CAIX
    carbonic anhydrase-IX, ECM extracellular matrix, FHL2 four and a half LIM domain
    protein 2, HIF-1α hypoxia inducible factor 1α, K19 keratin 19, Lef-1 lymphoid
    enhancer factor 1
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Itk
  - Slc22a3
  - Rip
  - Agfg1
  - Ptpn13
  - Ripk1
  - Rpain
  - Ctnnb1
  - Nfia
  - Nfib
  - Nfix
  - Krt19
  - Epcam
  - Map2k1
  - Mapk3
  - Lef1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Myc
  - Nol3
  - Pou5f1
  - Adam17
  - Fhl2
  - Egfr
  - Mapk1
  - Egf
  - Cdh2
  - Prom1
  - Tgfb1
  - Mapk8
  - Nanog
  - Sox2
  - Car9
  - Jun
  - Cd274
  - Ephb2
  - Trav6-3
  - Cd3e
  - Cd247
  - D9Mgc45e
  - Pdcd1
  - ITK
  - SLC22A3
  - AGFG1
  - RIPK1
  - DCAF1
  - RPAIN
  - CTNNB1
  - NFIA
  - NFIB
  - NFIC
  - NFIX
  - ESCO1
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - KRT19
  - EPCAM
  - MAP2K1
  - MAPK3
  - LEF1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - ATP8A2
  - MYC
  - POU5F1
  - POU5F1P3
  - POU5F1P4
  - ADAM17
  - FHL2
  - EGFR
  - MAPK1
  - EGF
  - CDH2
  - PROM1
  - TGFB1
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - MAPK8
  - MAPK9
  - MAPK10
  - NANOG
  - SOX2
  - CA9
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - CD274
  - EPHB2
  - ACOX1
  - SCP2
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD247
  - CD3D
  - CD3E
  - CD3G
  - PDCD1
  - RPL17
  - SNCA
  - SPATA2
  - RPL17-C18orf32
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - La
  - rip
  - ripp
  - arm
  - rl
  - pan
  - Ras64B
  - Ras85D
  - Raf
  - ATPsynbeta
  - Atpalpha
  - Low
  - Tace
  - CadN
  - bsk
  - CAH9
  - AP-1gamma
  - Jra
  - kay
  - Erk7
  - Scox
  - Tcr
  - ATP
  - NANOG
  - la Stemness
  - Hypoxia
  - HIF-10 hypoxia
  - tumor
---
